Death receptor-mediated liver injury

Seminars in Liver Disease

Volumn 27, Issue 4, 2007, Pages 327-338

  Akazawa, Yuko ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Caspase inhibition; Fibrosis; Lipoapotosis

Indexed keywords

ALDEHYDE DEHYDROGENASE; BH3 PROTEIN; CASPASE 10; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CATHEPSIN B; COLLAGEN TYPE 1; CYTOKERATIN; CYTOKERATIN 18; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR 1; UBIQUITIN PROTEIN LIGASE E3; UNINDEXED DRUG;

ALCOHOL LIVER DISEASE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL SURVIVAL; CHRONIC LIVER DISEASE; CLINICAL FEATURE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; LIVER FIBROSIS; LIVER INJURY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CASPASES; HUMANS; LIVER; LIVER DISEASES; MODELS, BIOLOGICAL; RECEPTORS, DEATH DOMAIN; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 35948933964     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991510     Document Type: Article

References (111)

1. Yoon JH, Gores GJ. Death receptor-mediated apoptosis and the liver. J Hepatol 2002;37:400-410
2. Ockner RK. Apoptosis and liver diseases: recent concepts of mechanism and significance. J Gastroenterol Hepatol 2001;16:248-260
3. Nagata S. Apoptosis by death factor. Cell 1997;88:355-365
4. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004;39:273-278
5. Tanaka M, Suda T, Yatomi T, et al. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 1997;158:2303-2309
6. Bajt ML, Lawson JA, Vonderfecht SL, et al. Protection against Fas receptor-mediated apoptosis in hepatocytes and nonparenchymal cells by a caspase-8 inhibitor in vivo: evidence for a postmitochondrial processing of caspase-8. Toxicol Sci 2000;58:109-117
7. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000;1:489-495
8. Zender L, Hutker S, Liedtke C, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003;100:7797-7802
9. Chen J, Nagayama T, Jin K, et al. Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. J Neurosci 1998;18:4914-4928
10. Strobel T, Swanson L, Korsmeyer S, et al. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 1996;93:14094-14099
11. Ekert PG, Read SH, Silke J, et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol 2004;165:835-842
12. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995;11:294-300
13. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-467
14. Yue HH, Diehl GE, Winoto A. Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice. Cell Death Differ 2005;12:94-97
15. Wang Y, Cui F, Lv Y, et al. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology 2004;39:318-324
16. Nakamoto Y, Kaneko S, Fan H, et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 2002;196:1105-1111
17. Hoffmann A, Xia Y, Verma IM. Inflammatory tales of liver cancer. Cancer Cell 2007;11:99-101
18. Guicciardi ME, Gores GJ. The Fas/FasL signaling pathway. In: Dufour J-F, Clavien P-A, eds. Signaling Pathways in Liver Diseases. Berlin, Heidelberg: Springer-Verlag; 2005:129-138
19. Peter ME, Krammer PH. The CD95(APO-1/Fas) Dros Inf ServC and beyond. Cell Death Differ 2003;10:26-35
20. Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (Dros Inf ServC) with the receptor. EMBO J 1995;14:5579-5588
21. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271:4961-4965
22. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-1687
23. Baskin-Bey ES, Gores GJ, Death by association: BH3 domain-only proteins and liver injury. Am J Physiol Gastrointest Liver Physiol 2005;289:G987-G990
24. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-730
25. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005;17:617-625
26. Kurosawa H, Que FG, Roberts LR, et al. Hepatocytes in the bile duct-ligated rat express Bcl-2. Am J Physiol 1997;272(6 Pt 1):G1587-G1593
27. Tzung SP, Fausto N, Hockenbery DM. Expression of Bcl-2 family during liver regeneration and identification of Bcl-x as a delayed early response gene. Am J Pathol 1997;150:1985-1995
28. Li H, Zhu H, Xu CJ, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501
29. Li S, Zhao Y, He X, et al. Relief of extrinsic pathway inhibition by the Bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J Biol Chem 2002;277:26912-26920
30. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682
31. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 2003;139:89-97
32. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14:359-372
33. Wu GS, Burns TF, Zhan Y, et al. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999;59:2770-2775
34. Thon L, Mathieu S, Kabelitz D, et al. The murine TRAIL receptor signals caspase-independent cell death through ceramide. Exp Cell Res 2006;312:3808-3821
35. van der Sloot AM, Tur V, Szegezdi E, et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 2006;103:8634-8639
36. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162
37. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163
38. Sadarangani A, Kato S, Espinoza N, et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 2007;12:73-85
39. Yagita H, Takeda K, Hayakawa Y, et al. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004;95:777-783
40. Janssen HL, Higuchi H, Abdulkarim A, et al. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 2003;39:414-420
41. Higuchi H, Bronk SF, Takikawa Y, et al. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 2001;276:38610-38618
42. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65
43. Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med 2004;8:445-454
44. Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006;290:G583-G589
45. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-190
46. Wullaert A, Heyninck K, Beyaert R. Mechanisms of crosstalk between TNF-induced NF-kappaB and JNK activation in hepatocytes. Biochem Pharmacol 2006;72:1090-1101
47. Chen X, Ding WX, Ni HM, et al. Bid-independent mitochondrial activation in tumor necrosis factor alpha-induced apoptosis and liver injury. Mol Cell Biol 2007;27:541-553
48. Kamata H, Honda S, Maeda S, et al. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120:649-661
49. Guicciardi ME, Deussing J, Miyoshi H, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000;106:1127-1137
50. Werneburg N, Guicciardi ME, Yin XM, et al. TNF-alpha-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. Am J Physiol Gastrointest Liver Physiol 2004;287:G436-G443
51. Werneburg NW, Guicciardi ME, Bronk SF, et al. Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent. Am J Physiol Gastrointest Liver Physiol 2002;283:G947-G956
52. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene 2004;23:2881-2890
53. Guicciardi ME, Bronk SF, Werneburg NW, et al. Bid is upstream of lysosome-mediated caspase 2 activation in tumor necrosis factor alpha-induced hepatocyte apoptosis. Gastroenterology 2005;129:269-284
54. Baskin-Bey ES, Canbay A, Bronk SF, et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2005;288:G396-G402
55. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003;38:1188-1198
56. Reuben A. Alcohol and the liver. Curr Opin Gastroenterol 2006;22:263-271
57. Kawahara H, Matsuda Y, Takase S. Is apoptosis involved in alcoholic hepatitis? Alcohol Alcohol Suppl 1994;29:113-118
58. Natori S, Rust C, Stadheim LM, et al. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001;34:248-253
59. Ribeiro PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004;99:1708-1717
60. Zhou Z, Sun X, Kang YJ. Ethanol-induced apoptosis in mouse liver: Fas- and cytochrome c-mediated caspase-3 activation pathway. Am J Pathol 2001;159:329-338
61. Deaciuc IV, Fortunato F, D'Souza NB, et al. Modulation of caspase-3 activity and Fas ligand mRNA expression in rat liver cells in vivo by alcohol and lipopolysaccharide. Alcohol Clin Exp Res 1999;23:349-356
62. Minana JB, Gomez-Cambronero L, Lloret A, et al. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology 2002;35:1205-1214
63. Ramalho RM, Cortez-Pinto H, Castro RE, et al. Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2006;18:21-29
64. Bird GL, Sheron N, Goka AK, et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-920
65. Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-952
66. Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997;26:1530-1537
67. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37:448-455
68. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol 2006;44:197-208
69. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845
70. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006;44:27-33
71. Nehra V, Angulo P, Buchman AL, et al. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 2001;46:2347-2352
72. Malhi H, Bronk SF, Werneburg NW, et al. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006;281:12093-12101
73. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-443
74. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001;281:G1135-G1139
75. Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004;40:185-194
76. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-350
77. Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepat 2003;10:335-342
78. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994;179:841-848
79. Liu YG, Liu SX, Liang XH, et al. Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochem Biophys Res Commun 2007;352:329-334
80. Chisari FV. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Top Microbiol Immunol 1996;206:149-173
81. Lee JY, Chae DW, Kim SM, et al. Expression of FasL and perforin/granzyme B mRNA in chronic hepatitis B virus infection. J Viral Hepat 2004;11:130-135
82. Mochizuki K, Hayashi N, Hiramatsu N, et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996;24:1-7
83. Song le H, Binh VQ, Duy DN, et al. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus. J Med Virol 2004;73:244-249
84. Fang JW, Shen WW, Meager A, et al. Activation of the tumor necrosis factor-alpha system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol 1996;91:748-753
85. Marinos G, Naoumov NV, Rossol S, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995;108:1453-1463
86. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1997;94:8744-8749
87. Mundt B, Kuhnel F, Zender L, et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003;17:94-96
88. Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001;31:3138-3146
89. Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100
90. Han LH, Sun WS, Ma CH, et al. Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol 2002;8:1077-1080
91. Liang X, Liu Y, Zhang Q, et al. Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immunol 2007;178:503-510
92. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26(3 suppl 1):62S-65S
93. Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ 2003;10(suppl 1):S48-S58
94. Hiramatsu N, Hayashi N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994;19:1354-1359
95. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004;40:1078-1087
96. Zhu N, Khoshnan A, Schneider R, et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998;72:3691-3697
97. Tokushige K, Yamaguchi N, Ikeda I, et al. Significance of soluble TNF receptor-I in acute-type fulminant hepatitis. Am J Gastroenterol 2000;95:2040-2046
98. Chou AH, Tsai HF, Wu YY, et al. Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 2005;174:2160-2166
99. Machida K, Tsukiyama-Kohara K, Seike E, et al. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem 2001;276:12140-12146
100. Saito K, Meyer K, Warner R, et al. Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol 2006;80:4372-4379
101. Hsu EC, Hsi B, Hirota-Tsuchihara M, et al. Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat Biotechnol 2003;21:519-525
102. Schiff ER, Pockros P, Schiffman ML, et al. Oral IDN-6556, an anti-apoptotic caspase inhibitor, lowers aminotransferases in HCV patients. J Hepatol 2004;40(suppl 1):24
103. Canbay A, Feldstein A, Baskin-Bey E, et al. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004;308:1191-1196
104. Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-663
105. Canbay A, Guicciardi ME, Higuchi H, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003;112:152-159
106. Anan A, Baskin-Bey ES, Bronk SF, et al. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 2006;43:335-344
107. Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;121:685-698
108. Elsharkawy AM, Wright MC, Hay RT, et al. Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology 1999;30:761-769
109. Taimr P, Higuchi H, Kocova E, et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003;37:87-95
110. Fischer R, Carters A, Reinehr R, et al. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 2002;123:845-861
111. Jeong WI, Park O, Radaeva S, et al. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006;44:1441-1451